AGC Bi­o­log­ics hit with 483 for poor dis­crep­an­cy in­ves­ti­ga­tion prac­tices, qual­i­ty con­trol is­sues at Wash­ing­ton site

CD­MO ACG Bi­o­log­ics re­ceived an FDA 483 let­ter, pub­lished on the FDA web­site this week, not­ing one of its sites failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.